Targeted Delivery of Protein and Gene Medicines Through the Blood–Brain Barrier

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 4, 2015, Pages 347-361

  Pardridge, W M ^a  

^a ArmaGen Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; RECOMBINANT PROTEIN;

ANIMAL; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE THERAPY; GENE TRANSFER; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL PRODUCTS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; RECOMBINANT PROTEINS;

EID: 84929138470     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.18     Document Type: Article

References (75)

1. The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS (Phase III). Neurology 52, 1427–1433 (1999).
2. Miller, R.G. et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39, 256–260 (1996).
3. Poduslo, J.F. & Curran, G.L. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res. 36, 280–286 (1996).
4. Garbuzova-Davis, S. et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 1157, 126–137 (2007).
5. Bogousslavsky, J. et al. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc. Dis. 14, 239–251 (2002).
6. Fisher, M. et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 15, 953– 959 (1995).
7. Latour, L.L., Kang, D.W., Ezzeddine, M.A., Chalela, J.A. & Warach, S. Early blood-brain barrier disruption in human focal brain ischemia. Ann. Neurol. 56, 468–477 (2004).
8. Belayev, L., Busto, R., Zhao, W. & Ginsberg, M.D. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739, 88–96 (1996).
9. Nutt, J.G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69–73 (2003).
10. Yan, Q., Matheson, C., Lopez, O.T. & Miller, J.A. The biological responses of axotomized adult motoneurons to brain-derived neurotrophic factor. J. Neurosci. 14, 5281–5291 (1994).
11. Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow. Metab. 32, 1959–1972 (2012).
12. Lang, A.E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459–466 (2006).
13. Salvatore, M.F. et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 202, 497–505 (2006).
14. Ehrenreich, H. et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40, e647–e656 (2009).
15. Banks, W.A., Jumbe, N.L., Farrell, C.L., Niehoff, M.L. & Heatherington, A.C. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur. J. Pharmacol. 505, 93–101 (2004).
16. Boado, R.J., Hui, E.K., Lu, J.Z. & Pardridge, W.M. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J. Pharmacol. Exp. Ther. 333, 961–969 (2010).
17. Reiber, H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor. Neurol. Neurosci. 21, 79– 96 (2003).
18. Vellas, B. et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 9, 438–444 (2013).
19. Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–919 (2000).
20. Boado, R.J., Zhang, Y., Zhang, Y., Xia, C.F. & Pardridge, W.M. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug. Chem. 18, 447–455 (2007).
21. Schlageter, N.L., Carson, R.E. & Rapoport, S.I. Examination of bloodbrain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J. Cereb. Blood Flow. Metab. 7, 1–8 (1987).
22. Seubert, P. et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis. 5, 65–71 (2008).
23. Pardridge, W.M., Oldendorf, W.H., Cancilla, P. & Frank, H.J. Bloodbrain barrier: interface between internal medicine and the brain. Ann. Intern. Med. 105, 82–95 (1986).
24. Duvernoy, H.M., Delon, S. & Vannson, J.L. Cortical blood vessels of the human brain. Brain Res. Bull. 7, 519–579 (1981).
25. Cornford, E.M., Hyman, S., Cornford, M.E. & Caron, M.J. Glut1 glucose transporter activity in human brain injury. J. Neurotrauma 13, 523–536 (1996).
26. Pardridge, W.M. & Boado, R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 503, 269–292 (2012).
27. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3–14 (2005).
28. Uchida, Y. et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333–345 (2011).
29. Boado, R.J., Li, J.Y., Nagaya, M., Zhang, C. & Pardridge, W.M. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 96, 12079–12084 (1999).
30. Kageyama, T. et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 879, 115–121 (2000).
31. Pardridge, W.M., Eisenberg, J. & Yang, J. Human blood-brain barrier insulin receptor. J. Neurochem. 44, 1771–1778 (1985).
32. Pardridge, W.M., Eisenberg, J. & Yang, J. Human blood-brain barrier transferrin receptor. Metabolism 36, 892–895 (1987).
33. Duffy, K.R. & Pardridge, W.M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420, 32–38 (1987).
34. Fishman, J.B., Rubin, J.B., Handrahan, J.V., Connor, J.R. & Fine, R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18, 299–304 (1987).
35. Skarlatos, S., Yoshikawa, T. & Pardridge, W.M. Transport of [125I]transferrin through the rat blood-brain barrier. Brain Res. 683, 164–171 (1995).
36. Pardridge, W.M., Kang, Y.S., Buciak, J.L. & Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12, 807–816 (1995).
37. Pardridge, W.M., Buciak, J.L. & Friden, P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259, 66–70 (1991).
38. Zhou, Q.H., Boado, R.J. & Pardridge, W.M. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J. Drug Target 20, 715–719 (2012).
39. Boado, R.J., Zhang, Y., Wang, Y. & Pardridge, W.M. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 102, 1251–1258 (2009).
40. Boado, R.J., Hui, E.K., Lu, J.Z. & Pardridge, W.M. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug. Chem. 24, 97–104 (2013).
41. Boado, R.J., Ka-Wai Hui, E., Zhiqiang Lu, J. & Pardridge, W.M. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol. Bioeng. 111, 2317–2325 (2014).
42. Clark, I.A., Alleva, L.M. & Vissel, B. The roles of TNF in brain dysfunction and disease. Pharmacol. Ther. 128, 519–548 (2010).
43. Boado, R.J., Hui, E.K., Lu, J.Z., Zhou, Q.H. & Pardridge, W.M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 146, 84–91 (2010).
44. Zhou, Q.H.Sumbria, R., Hui, E.K.-W., Lu, J.Z., Boado, R.J. & Pardridge, W.M. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J. Pharmacol. Exp. Ther. 339, 618– 623 (2011).
45. Sumbria, R.K., Boado, R.J. & Pardridge, W.M. Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein. J. Cereb. Blood Flow Metab. 32, 1933–1938 (2012).
46. Boado, R.J. & Pardridge, W.M. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 37, 2299– 2304 (2009).
47. Zhou, Q.H., Boado, R.J., Hui, E.K., Lu, J.Z. & Pardridge, W.M. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glialderived neurotrophic factor fusion protein. Drug Metab. Dispos. 39, 1149–1154 (2011).
48. Boado, R.J., Zhang, Y., Zhang, Y., Wang, Y. & Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng. 100, 387–396 (2008).
49. Zhou, Q.H., Boado, R.J., Lu, J.Z., Hui, E.K. & Pardridge, W.M. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab. Dispos. 38, 566–572 (2010).
50. Zhou, Q.H., Boado, R.J., Lu, J.Z., Hui, E.K., & Pardridge, W.M. Reengineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol. Pharm. 7, 2148–2155 (2010).
51. Fu, A., Zhou, Q.H., Hui, E.K., Lu, J.Z., Boado, R.J. & Pardridge, W.M. Intravenous treatment of experimental Parkinson’s disease in the mouse with an IgG-GDNF fusion protein that penetrates the bloodbrain barrier. Brain Res. 1352, 208–213 (2010).
52. Zhou, Q.H., Hui, E.K., Lu, J.Z., Boado, R.J. & Pardridge, W.M. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson’s disease in the mouse. Brain Res. 1382, 315–320 (2011).
53. Sumbria, R.K., Boado, R.J. & Pardridge, W.M. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins. Brain Res. 1507, 91–96 (2013).
54. Yu, Y.J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3, 84ra44 (2011).
55. Niewoehner, J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49–60 (2014).
56. Gu, J. & Ghayur, T. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Methods Enzymol. 502, 25–41 (2012).
57. Atwal, J.K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci. Transl. Med. 3, 84ra43 (2011).
58. Sumbria, R.K., Hui, E.K., Lu, J.Z., Boado, R.J. & Pardridge, W.M. Disaggregation of amyloid plaque in brain of Alzheimer’s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol. Pharm. 10, 3507–3513 (2013).
59. Cheng, S.H. & Smith, A.E. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 10, 1275– 1281 (2003).
60. Boado, R.J., Hui, E.K., Lu, J.Z. & Pardridge, W.M. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol. 144, 135– 141 (2009).
61. Boado, R.J., Hui, E.K., Lu, J.Z., Zhou, Q.H. & Pardridge, W.M. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol. Pharm. 8, 1342–1350 (2011).
62. Boado, R.J., Zhang, Y., Zhang, Y., Xia, C.F., Wang, Y. & Pardridge, W.M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 99, 475–484 (2008).
63. Boado, R.J., Lu, J.Z., Hui, E.K. & Pardridge, W.M. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate bloodbrain barrier and reduces glycosoaminoglycans in Sanfilippo type a cells. Mol. Pharm. 11, 2928–2934 (2014).
64. Boado, R.J., Lu, J.Z., Hui, E.K., Sumbria, R.K. & Pardridge, W.M. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase A and a monoclonal antibody against the human insulin receptor. Biotechnol. Bioeng. 110, 1456–1465 (2013).
65. Wu, D., Yang, J. & Pardridge, W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100, 1804–1812 (1997).
66. Zhou, Q.H., Lu, J.Z., Hui, E.K., Boado, R.J. & Pardridge, W.M. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug. Chem. 22, 1611–1618 (2011).
67. Kurihara, A. & Pardridge, W.M. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res. 59, 6159–6163 (1999).
68. Suzuki, T., Wu, D., Schlachetzki, F., Li, J.Y., Boado, R.J. & Pardridge, W.M. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45, 1766–1775 (2004).
69. Zhang, Y., Calon, F., Zhu, C., Boado, R.J. & Pardridge, W.M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14, 1–12 (2003).
70. Zhang, Y., Schlachetzki, F. & Pardridge, W.M. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7, 11–18 (2003).
71. Zhang, Y., Schlachetzki, F., Li, J.Y., Boado, R.J. & Pardridge, W.M. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9, 465–472 (2003).
72. Zhu, C., Zhang, Y., Zhang, Y.F., Li, J.Y., Boado, R.J. & Pardridge, W.M. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J. Gene Med. 6, 906–912 (2004).
73. Zhang, Y., Schlachetzki, F., Zhang, Y.F., Boado, R.J. & Pardridge, W.M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 15, 339–350 (2004).
74. Zhang, Y., Zhu, C. & Pardridge, W.M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67– 72 (2002).
75. Zhang, Y., Bryant, J., Zhang, Y.F., Charles, A., Boado, R.J. & Pardridge, W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10, 3667–3677 (2004).